The subscription period for Diamyd Medical's rights issue has begun - the major owners fully subscribe for their shares

Diamyd Medical announces that the major owners, Bertil Lindkvist and Anders Essen-Möller, intend to fully subscribe for their shares, corresponding to a total of approximately SEK 19.9 million or approximately 29% of the current rights issue totaling SEK 68.8 million. The issue is guaranteed to 80%. The Board is entitled to decide on an additional SEK 20 million in case of oversubscription.Diamyd Medical's rights issue aims to clearly move positions towards potential partners and take the diabetes vaccine Diamyd® closer to market. A follow-up pivotal phase II study, where the diabetes